Asthma in Adults

Description

Treatment

Treating an Acute Attack in the Hospital. An acute attack may require hospitalization. Laboratory tests, an electrocardiogram (ECG), and a chest x-ray are performed to determine lung function, oxygen levels, and other indications of severity or rule out other causes. Depending on the results, the following treatments may be given:

• Beta2-agonists are the standard therapy. They may be administered with a nebulizer (a device that administers the drug in a fine spray) or given hourly with an inhaler. Studies are suggesting the use of inhaler is equally or possibly more effective than a nebulizer. Intravenous delivery is not recommended in most cases.
• A corticosteroid (commonly called a steroid) given within the first hour helps reduce the need for hospitalization. They are typically administered intravenously or as an injection in adults. Lower doses work as well as higher ones in these situations.
• Intravenous magnesium opens airways and has been under investigation as an additional treatment. Although its benefits have been debated, important studies in 2002 reported that intravenous magnesium enhances the effects of other treatments in patients with very severe acute asthma and is associated with few or no serious side effects.
• Oxygen is usually administered, and can be life saving in severe cases.
• In life-threatening situations, the patient may require mechanical ventilation.
• Of note, antibiotics are not useful for asthma attacks if there is no strong evidence of the presence of a bacterial infection. (Viral infections, most often colds and flus, are more likely to trigger an asthma attack. In such cases, antibiotics do not appear to be beneficial and may have adverse effects.)

Discharge and Relapse After Hospitalization. It typically takes about three to four hours to determine if a patient can be safely sent home or if they need to stay. Patients are generally discharged under the following circumstances:

• When symptoms are gone or are minimal, and
• The peak expiratory flow rate is 70% or more of the predicted rate.

Discharged patients generally take oral corticosteroids for five to seven days. Despite reasonable precautions, about 20% of patients relapse within two weeks, although the risk is very low if they keep taking their medication after they leave.

Guidelines for Treating Asthma at Home

Avoiding allergens, following appropriate drug treatments, and home monitoring are key elements in preventing dangerous asthma attacks and hospitalization. A combination of medications is important and effective for both treating and preventing asthma attacks. In addition, good communication between the physician and patient is a key factor in a successful management program. Written action plans, which instruct individual patients how to properly respond to changes in their unique symptoms, are proving to be a very important element in successful self-management of asthma.

Understanding the Difference Between Treating Symptoms and Controlling the Disease

Patients can greatly reduce the frequency and severity of asthma attacks by understanding the difference between coping with asthma attacks and controlling the disease over time. According to a few studies, most patients do not discriminate between medications that provide rapid short-term relief and long-term symptom control.

Medications for asthma are categorized by their ability to achieve either of the following:

• Drugs Used to Open Airways for Symptom Relief. Medications that open the airways (bronchodilators) are used promptly for any moderate or severe asthma attack. Usually, these agents are short-acting beta-adrenergic agonists (beta2-agonists). Others used in special cases include theophylline and certain anticholinergic agents. None of these agents have any effect on the disease process itself. They are only useful for treating symptoms.
• Maintenance Drugs Used to Control Long-Term Inflammation and Prevent Long Injury. Simply coping with asthma symptoms without also controlling the damaging inflammatory response is a common and serious error. For adults and children over five with moderate to severe persistent asthma experts now recommend an inhaled corticosteroids and long-acting beta2-agonists, such as salmeterol (Serevent).

In spite of the strong evidence supporting the use of anti-inflammatory agents for controlling the disease, a significant number of moderate or severely asthmatic patients still overuse their inhaled beta-agonists and underuse their corticosteroid medications. The over-use of bronchodilator can have serious immediate consequences and not using steroids can lead to permanent lung damage. Furthermore, the patients who underuse steroids tend to be elderly, the group at highest risk for severe asthma.

Administering Inhaled Drugs

Most asthma drugs are inhaled using various forms of inhalers or nebulizers. Inhaled agents must be used regularly as prescribed and the patient carefully trained in their use in order for them to be effective and safe. The basic devices are the metered-dose inhaler (MDI), breath-actuated inhalers, dry powder inhalers, and nebulizers.

MDIs have used chlorofluorocarbons (CFCs) as their propellants, which are damaging to the environment. Over time CFS is being replaced with other propellants (e.g., hydrofluoroalkane) that are equally effective to CFCs, are environmentally safe, and do not chill the device as CFCs do. Devices that don't use propellants at all are also now available.

Metered-Dose Inhaler. The standard device for administering any asthma medication has been the metered-dose inhaler (MDI). This device, particularly when used with a holding chamber, allows precise doses to be delivered directly to the lungs.

Click the icon to see an image of a holding chamber.

MDI-delivered drugs must be used regularly as prescribed and the patient carefully trained in their use in order for them to be effective and safe. Some patients hold the MDI too close to their mouths, or even inside them. Others may exhale too forcefully before inhalation. The holding chamber, or spacer, allows the patient additional time to inhale the medication and so improves delivery. They vary, however, in their ability to deliver medication. For example, in one study the AiroChamber-Plus was more effective than the EasiVent in delivering an inhaled steroid. It should be noted that often MDIs continue to deliver propellant after the drug has been used up. Patients should track their medicine and throw the device away when the last dose has been administered.

Click the icon to see an illustrated series detailing metered dose inhaler use.

Breath-Actuated Inhalers. Breath-actuated rotary inhalers (e.g., Easi-Breathe and Autohaler) deliver the drug directly to the back of the throat as the user inhales. Their primary advantage over the MDI is their ease of use. They also do not use CFCs as propellants. In comparison studies, patients have been very successful with the breath-actuated inhalers.

Dry Powder Inhalers. Dry powder inhalers (DPIs) deliver a powdered form of beta2 agonists or corticosteroids directly into the lungs. They also do not use CFCs. Such devices include Rotahaler, Spinhaler, Turbohaler, Clickhaler, Easyhaler, Diskhaler, Discus, Twisthaler, Spiros, and others. DPIs are as effective as the older devices, and generally have a better taste and are easier to manage. They may differ among themselves, however, in their ability to deliver drugs into the airways. In one study, for example, the Turbohaler was easier to use than the Diskhaler and so achieved better delivery. The Discus is another effective DPI; it has a dose counter and protects against exhalation effects. More research is needed.

Humidity or extreme temperatures can affect their performance, so they should not be stored in humid places (e.g., bathroom cabinets) or locations subject to high temperatures (e.g., glove compartments during summer months).

Dry-powder may cause tooth erosion and children are advised to rinse their mouths out right after taking the drug and to brush twice a day with a fluoride toothpaste.

Other Hand-Held Inhalers. Respimat delivers a fine-mist spray that is created by forcing the liquid medication through nozzles. It does not use any propellant.

Nebulizers. A nebulizer is a device that administers the drug in a fine spray that the patient breathes in. They are mostly used in hospital settings or when the patient cannot use an inhaler. Nebulizers may be important for delivering newer agents used in asthma treatment.

Click the icon to see an illustrated series detailing nebulizer use.

Monitoring

People who self-manage their asthma using daily monitoring of peak air flow and adjusting their medications as needed have fewer hospitalizations, fewer unplanned doctors visits, and, generally, a better quality of life than those who rely only on the occasional physician or emergency room visit to control symptoms. Physicians recommend that patients with even mild asthma monitor their own conditions.

In general, monitoring involves the following steps:

• A peak flow meter is the standard monitoring device for measuring peak expiratory flow rate (PEFR).

Click the icon to see an image of a peak flow meter.

• Patients with severe asthma should take PEFR readings two or three times a day. The overall goal should be to achieve less than a 20% (and ideally only 10%) variation in readings between evening and morning rates. For mild to moderate asthma, a single determination each morning usually suffices, but patients should check with their physicians.
• It is important to use the meter at the same times each day and to stand or sit in the same position in order to keep an accurate record.
• Patients should keep an ongoing record of their peak flow readings to help them detect worsening of their condition.
• They should also record attacks, exposure to any allergens or triggers, and medications taken.
• After about two months, patients and physicians can use the data recorded for administering medications effectively and to recognize problems before they become serious.

In general, many people fail to monitor their asthma. Experts believe that, ideally, portable monitors should be available to measure forced expiratory volume (FEV1), which is more accurate gauge of lung function, and the results should be electronically transmitted to the physician.

New monitoring devices are showing promise in accomplishing one or more of these goals, although they are not covered by most insurers. For example, the AirWatch is a hand-held digital monitor that measures and displays the rate of airflow and compares it to the rates from previous days. Once a month, or whenever there is a problem, the person plugs the device into a standard telephone jack and the daily readings are sent to an automated data center which creates tables and charts for the patient and the doctor.